NDC 31722-001

lamivudine

Lamivudine

lamivudine is a Oral Tablet, Film Coated in the Human Prescription Drug category. It is labeled and distributed by Camber Pharmaceuticals, Inc.. The primary component is Lamivudine.

Product ID31722-001_ac179816-95cd-4657-abd1-198f7b0f0398
NDC31722-001
Product TypeHuman Prescription Drug
Proprietary Namelamivudine
Generic NameLamivudine
Dosage FormTablet, Film Coated
Route of AdministrationORAL
Marketing Start Date2019-03-21
Marketing CategoryANDA / ANDA
Application NumberANDA211306
Labeler NameCamber Pharmaceuticals, Inc.
Substance NameLAMIVUDINE
Active Ingredient Strength100 mg/1
Pharm ClassesHepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC],Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC],Nucleoside Analog [EXT],Nucleoside Reverse Transcriptase Inhibitors [MoA]
NDC Exclude FlagN
Listing Certified Through2020-12-31

Packaging

NDC 31722-001-02

20 BLISTER PACK in 1 CARTON (31722-001-02) > 10 TABLET, FILM COATED in 1 BLISTER PACK
Marketing Start Date2019-03-21
NDC Exclude FlagN
Sample Package?N

NDC SPL Data Element Entries

NDC 31722-001-02 [31722000102]

lamivudine TABLET, FILM COATED
Marketing CategoryANDA
Application NumberANDA211306
Product TypeHUMAN PRESCRIPTION DRUG
Marketing Start Date2019-03-21

NDC 31722-001-60 [31722000160]

lamivudine TABLET, FILM COATED
Marketing CategoryANDA
Application NumberANDA211306
Product TypeHUMAN PRESCRIPTION DRUG
Marketing Start Date2019-03-21

Drug Details

Active Ingredients

IngredientStrength
LAMIVUDINE100 mg/1

OpenFDA Data

SPL SET ID:e90671c6-7fff-48f4-8898-29f02d049c8b
Manufacturer
UNII
RxNorm Concept Unique ID - RxCUI
  • 205328
  • UPC Code
  • 0331722001601
  • Pharmacological Class

    • Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC]
    • Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC]
    • Nucleoside Analog [EXT]
    • Nucleoside Reverse Transcriptase Inhibitors [MoA]
    • Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC]
    • Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC]
    • Nucleoside Analog [EXT]
    • Nucleoside Reverse Transcriptase Inhibitors [MoA]

    NDC Crossover Matching brand name "lamivudine" or generic name "Lamivudine"

    NDCBrand NameGeneric Name
    0904-6583LAMIVUDINElamivudine
    10135-605LamivudineLamivudine
    31722-001lamivudinelamivudine
    31722-752LamivudineLamivudine
    31722-753LamivudineLamivudine
    31722-754LamivudineLamivudine
    33342-001LamivudineLamivudine
    33342-002LamivudineLamivudine
    68180-603LamivudineLamivudine
    68180-602LamivudineLamivudine
    69097-167LAMIVUDINELAMIVUDINE
    69097-166LAMIVUDINELAMIVUDINE
    70518-0540LamivudineLamivudine
    70518-0440LamivudineLamivudine
    70518-0513LamivudineLamivudine
    70518-0690LamivudineLamivudine
    70518-1083LamivudineLamivudine
    70518-1084LamivudineLamivudine
    70518-1634LamivudineLamivudine
    70518-1933LamivudineLamivudine
    50268-460LamivudineLamivudine
    50268-459LamivudineLamivudine
    50742-623LamivudineLamivudine
    50742-624LamivudineLamivudine
    51293-832LamivudineLamivudine
    53808-0843LAMIVUDINELAMIVUDINE
    53808-0844LAMIVUDINELAMIVUDINE
    54838-566LamivudineLamivudine
    57237-274LamivudineLamivudine
    60429-354LAMIVUDINELAMIVUDINE
    60687-362LamivudineLamivudine
    60429-353LAMIVUDINELAMIVUDINE
    60505-3250LamivudineLamivudine
    60505-3252LAMIVUDINELAMIVUDINE
    60505-3251LAMIVUDINELAMIVUDINE
    63629-5014LamivudineLamivudine
    64380-711LamivudineLamivudine
    64330-001LamivudineLamivudine
    64380-710LamivudineLamivudine
    65862-055LamivudineLamivudine
    65862-026LamivudineLamivudine
    65862-552LamivudineLamivudine
    65862-553LamivudineLamivudine
    65862-025LamivudineLamivudine
    66993-478LamivudineLamivudine
    69967-003LamivudineLamivudine
    69967-004LamivudineLamivudine
    70518-2067LamivudineLamivudine
    70518-2070LamivudineLamivudine
    0173-0662EPIVIRlamivudine

    © 2024 FDA.report
    This site is not affiliated with or endorsed by the FDA.